UroAlerts - Prostate Cancer Weekly

November 12, 2024

Videos

Peer-to-Peer Clinical Conversations

Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel

Steven Kregel

Andrea Miyahira hosts Steven Kregel to discuss a published paper on humanized mouse models for metastatic prostate cancer.

AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk and Active Surveillance - Andre Esteva

Andre Esteva

Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active surveillance patients.

Beyond the Abstracts

Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer - Beyond the Abstract

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence - Beyond the Abstract

Conference Coverage

ASTRO 2024: A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)

ASTRO 2024: A Digital Pathology MMAI Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer

ASTRO 2024: Validation of a Digital Pathology-Based MMAI Model in Oligometastatic Castration-Sensitive Prostate Cancer, including Patients from the STOMP and ORIOLE Phase II Randomized Trial

ASTRO 2024: Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol

ASTRO 2024: Impact of Hyaluronic Acid Rectal Spacer Quality Score and Fischer-Valuck Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal Toxicity Outcomes – An Australian Experience

Physician-Scientist Review Articles

Metastasis-Directed Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: New Frontiers in Advanced Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era

Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents.

Prostate cancer theragnostics biomarkers: An update.

Patients' anxieties and fears: a comparison between transrectal prostate biopsy and prostate MRI.

Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis.

A Randomized Controlled Trial of Gamification to Increase Physical Activity Among Black and Hispanic Breast and Prostate Cancer Survivors: Rationale and Design of the ALLSTAR Clinical Trial.

Advanced Imaging for Localized Prostate Cancer.

Clarity and Nucleus RadioPharma Sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.

Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.

Management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the role of Radiotherapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment

The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer.

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.

The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619.

5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer.

PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection.

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.

Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy.

Multidimensional Healthcare Access Barriers to Prostate-Specific Antigen Testing: A Nation-Wide Panel Study in the United States From 2006 to 2020.

Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer.

AI-ADC: Channel and Spatial Attention-Based Contrastive Learning to Generate ADC Maps from T2W MRI for Prostate Cancer Detection.

Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.

Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial.

Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.

Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC).

PSMA PET Improves Characterization of Dural-Based Intracranial Lesions in Patients with Metastatic Prostate Cancer - Beyond the Abstract

Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC